KITD, KIT digital, Inc.
** On its third quarter fiscal 2011, KITD posted record revenue of $62.3 million, an increase of 29% sequentially and 124% year over year.
Excluding the effect of acquired companies during the comparable periods, KITD estimates organic growth in third quarter fiscal 2011 was 11% sequentially and over 35% versus the same year-ago quarter.
KITD is a premium provider of end-to-end video management software and related services. The KIT Video Platform, KITD's cloud-based video asset management system, enables enterprise, media & entertainment and network operator clients to produce, manage and deliver multiscreen socially-enabled video experiences to audiences wherever they are.
More about KITD at www.kitd.com
STS, Supreme Industries Inc.
** STS reported that its consolidated net sales increased 19% to $72.8 million in the third quarter fiscal 2011, compared to the same period the prior year.
STS reported net income from continuing operations of $1.5 million, or $0.10 per diluted share, for the third quarter fiscal 2011, compared with income from continuing operations of $0.3 million, or $0.02 per diluted share, in the same period the prior year. Including the impact from discontinued operations, net income improved to $0.10 per diluted share, reversing the year-ago net loss of $0.01 per share.
STS is a nationwide manufacturer of specialized truck bodies produced to the specifications of its customers. STS also manufactures special-purpose ?shuttle-type? buses and armored vehicles.
More about STS at www.SupremeInd.com.
SVA, Sinovac Biotech Ltd.
** SVA reported positive top-line results from its phase II clinical trial for its proprietary inactivated vaccine against human enterovirus 71 or EV71, which causes hand, foot and mouth disease (HFMD), a contagious viral illness that commonly affects infants and children.
HFMD represent a very serious problem in China, some other Asian countries and other areas in recent years given that no vaccine and specific treatment is currently available to protect against this disease. EV71 represents a significant health threat to children as a growing number of HFMD cases have been reported in parts of Asia, including mainland China, Vietnam, Hong Kong, Singapore, South Korea, and Taiwan. According to the Chinese Ministry of Health's data available for the period from January 1 to September 30, 2011, the disease caused 399 deaths in China and over 1.2 million HFMD infection cases during the nine-month period, as reported by health authorities. In 2010, there were over 1.7 million reported EV71 infectious cases with over 800 fatal cases. In August of 2011, over 32,000 HFMD infectious cases were reported inVietnam with 81 deaths. HFMD is common among infants and children, as most of the recently reported cases have occurred in children under five years of age.
SVA is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza.
In 2009, SVA was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. SVA is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), pneumococcal polysaccharides, human rabies, HIB, rotavirus and epidemic meningitis, chickenpox and mumps & rubella.
More about SVA at www.sinovac.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.